Severe COVID-19 patients presented a significant reduction in s-VCAM-1 at days 3–4 (P < 0.050 vs. Admission) and the same happened for the group of critical COVID-19 at days 3–4 and days 5–8 (P < 0.050), but in critical COVID-19 on VV-ECMO patients, a significant reduction of s-VCAM-1 values was only observed at a later period, namely at weeks 2, 3 and 4 (P < 0.050, P < 0.010 and P < 0.050 vs. Admission, respectively). The gene discussed is VCAM1; the disease is COVID-19.